The global induced pluripotent stem cells market comprises regenerative and iPS cells, which can self-renew and differentiate into various cell types. iPS cells exhibit embryonic stem cell-like characteristics and properties including the ability to differentiate into all cell types in the human body. iPS cells are generated from adult somatic cells, typically isolated from skin or blood. They can be produced autologously without using embryos. iPS cells and their derivatives are finding applications in drug discovery and development, toxicology and preclinical research, disease modelling, and cell therapy.
The global induced pluripotent stem cells market is estimated to be valued at US$1,595.4 million in 2024 and is expected to exhibit a CAGR of 1.4% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Global Induced Pluripotent Stem Cells Market Demand are Takara Bio Inc., Thermo Fisher Scientific, Fujifilm Holdings Corporation, Astellas Pharma, Fate Therapeutics, Ncardia, ViaCyte, Cellular Dynamics International, Lonza, Blueprint Medicines and Other Prominent Players. Takara Bio Inc. and Thermo Fisher Scientific hold majority of the market share of the overall induced pluripotent stem cells market.
The key opportunities in the global induced pluripotent stem cells market include applications in drug discovery and development. Many pharmaceutical companies are adopting iPS cells as research models for drug screening and toxicity testing. iPS cells can be used as in vitro disease models to better understand disease pathology and identify potential therapeutic targets. This reduces dependence on animal models for preclinical research.
The global expansion of key players operating in the market through strategic collaborations and partnerships will further aid the growth of iPS cells. For instance, Fate Therapeutics recently entered into a strategic collaboration with Janssen Biotech to develop iPSC-derived cell therapy products for patients with various illnesses. Such initiatives facilitate wider availability and adoption of iPS cell technologies globally.
Market Drivers
Increased funding for stem cell research from public and private organizations is a key driver for the global induced pluripotent stem cells market. Heavy investments in iPS cell based therapy development, especially for conditions like Parkinson's disease, heart disease, dementia, etc. is fueling market growth. For example, Japanese government created a 5-year $1 billion initiative aimed at promoting iPS cell research and its applications.
Market Restraints
The high costs associated with developing and manufacturing iPS cell therapies pose a major challenge to market growth. Further, ethical concerns regarding use of human embryos is another restraint. Reaching clinical trials and gaining regulatory approvals also require considerable investments of time and resources. These factors hamper wider commercialization of iPS cell technologies currently.
Segment Analysis
The global induced pluripotent stem cells market can be segmented based on product type into instruments, culture media, and consumables. The consumables segment currently dominates the market due to increasing demand for various induced pluripotent stem cells based consumables like reagents, antibody, and primers among researchers and scientists for research activities and assays. The increasing usage of induced pluripotent stem cells for various disease modeling applications and toxicity screening is another key factor attributed to the large share of this segment.
Global Analysis
In terms of region, North America is anticipated to account for the dominant share in the global induced pluripotent stem cells market during the forecast period. Factors such as rising incidence of chronic diseases, growing geriatric population, surge in collaborations and partnerships between key industry players, and increasing funding for research activities in stem cell technology are expected to boost the growth of the induced pluripotent stem cells market in North America. The Asia Pacific region is projected to witness the fastest growth over the forecast period, owing to rising healthcare expenditure, improving healthcare infrastructure, increasing incidents of infectious and lifestyle diseases, supportive regulatory policies, and growing investments in stem cell research in several emerging Asian countries such as China, India and Japan.
Get more insights on Global Induced Pluripotent Stem Cells Market
Also read related article on Water & Wastewater Treatment Chemicals Market
Comments
0 comment